Immunic Inc banner

Immunic Inc
NASDAQ:IMUX

Watchlist Manager
Immunic Inc Logo
Immunic Inc
NASDAQ:IMUX
Watchlist
Price: 0.955 USD -4.5% Market Closed
Market Cap: $124.6m

During the last 3 months Immunic Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 45% over this period (open performance analysis).

The last transaction was made on Jun 13, 2025 by Nash Duane , who bought 16.7k USD worth of IMUX shares.

Last Transactions:
Nash Duane
$+16.7k
Tardio Jason
$+9.9k
Neermann Joerg
$+22.8k
Tardio Jason
$+9.9k
Vitt Daniel
$+11.6k
Vitt Daniel
$+11.6k
Neermann Joerg
$+53.9k
Whaley Glenn
$+32.1k
Rudick Richard Alan
$+100k
Rudick Richard Alan
$+100.4k
Vitt Daniel
$+18.3k
Whaley Glenn
$+8.8k
Neermann Joerg
$+59k
Neermann Joerg
$+43.6k
Neermann Joerg
$+25k
Vitt Daniel
$+10.8k
Whaley Glenn
$+7.5k
Vitt Daniel
$+15.5k
Whaley Glenn
$+10.7k
Muehler Andreas
$+17.9k
Whaley Glenn
$+15.2k
Nash Duane
$+50.3k
Whaley Glenn
$+14.8k
Vitt Daniel
$+9.6k
Nash Duane
$+9.8k
Nash Duane
$+51k
Muehler Andreas
$+155.5k
Whaley Glenn
$+16.5k
Whaley Glenn
$+19k
Groeppel Manfred
$-10.2k
Vitt Daniel
$-20.3k
Groeppel Manfred
$-72.2k
View All Transactions

During the last 3 months Immunic Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 45% over this period (open performance analysis).

The last transaction was made on Jun 13, 2025 by Nash Duane , who bought 16.7k USD worth of IMUX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
6
268.4k USD

Immunic Inc
Insider Trading Chart

Immunic Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Immunic Inc
Last Insider Transactions

Global
Insiders Monitor

Immunic Inc
Glance View

Market Cap
124.6m USD
Industry
Biotechnology

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

IMUX Intrinsic Value
7.655 USD
Undervaluation 88%
Intrinsic Value
Price $0.955

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett